Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by ROBERT A WOLFF and AHMED KASEB.
ROBERT A WOLFF
Connection Strength
3.216
AHMED KASEB
  1. Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab. Cancer Biomark. 2024; 41(1):83-91.
    View in: PubMed
    Score: 0.235
  2. Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients. Oncotarget. 2022 12 06; 13:1314-1321.
    View in: PubMed
    Score: 0.218
  3. Blockade of growth hormone receptor signaling by using pegvisomant: A functional therapeutic strategy in hepatocellular carcinoma. Front Oncol. 2022; 12:986305.
    View in: PubMed
    Score: 0.216
  4. Perioperative nivolumab monotherapy versus nivolumab plus ipilimumab in resectable hepatocellular carcinoma: a randomised, open-label, phase 2 trial. Lancet Gastroenterol Hepatol. 2022 03; 7(3):208-218.
    View in: PubMed
    Score: 0.205
  5. A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by 90Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma. J Hepatocell Carcinoma. 2021; 8:1129-1145.
    View in: PubMed
    Score: 0.200
  6. HepatoScore-14: Measures of Biological Heterogeneity Significantly Improve Prediction of Hepatocellular Carcinoma Risk. Hepatology. 2021 06; 73(6):2278-2292.
    View in: PubMed
    Score: 0.197
  7. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib. Oncotarget. 2021 Apr 13; 12(8):756-766.
    View in: PubMed
    Score: 0.195
  8. Impact of Integrating Insulin-Like Growth Factor 1 Levels into Model for End-Stage Liver Disease Score for Survival Prediction in Hepatocellular Carcinoma Patients. Oncology. 2020; 98(12):836-846.
    View in: PubMed
    Score: 0.188
  9. Origin and role of hepatic myofibroblasts in hepatocellular carcinoma. Oncotarget. 2020 Mar 31; 11(13):1186-1201.
    View in: PubMed
    Score: 0.181
  10. Molecular Profiling of Hepatocellular Carcinoma Using Circulating Cell-Free DNA. Clin Cancer Res. 2019 10 15; 25(20):6107-6118.
    View in: PubMed
    Score: 0.173
  11. Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma. Oncotarget. 2018 Dec 28; 9(102):37721-37732.
    View in: PubMed
    Score: 0.166
  12. Estrogen Replacement Reduces Risk and Increases Survival Times of Women With Hepatocellular Carcinoma. Clin Gastroenterol Hepatol. 2017 Nov; 15(11):1791-1799.
    View in: PubMed
    Score: 0.149
  13. Evaluating clinical and prognostic implications of Glypican-3 in hepatocellular carcinoma. Oncotarget. 2016 Oct 25; 7(43):69916-69926.
    View in: PubMed
    Score: 0.143
  14. Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma. Onco Targets Ther. 2016; 9:773-80.
    View in: PubMed
    Score: 0.136
  15. Validation of an IGF-CTP scoring system for assessing hepatic reserve in Egyptian patients with hepatocellular carcinoma. Oncotarget. 2015 Aug 28; 6(25):21193-207.
    View in: PubMed
    Score: 0.132
  16. Development and validation of insulin-like growth factor-1 score to assess hepatic reserve in hepatocellular carcinoma. J Natl Cancer Inst. 2014 May 09; 106(5).
    View in: PubMed
    Score: 0.120
  17. Phase I trial of single-photon emission computed tomography-guided liver-directed radiotherapy for patients with low functional liver volume. JNCI Cancer Spectr. 2024 Apr 30; 8(3).
    View in: PubMed
    Score: 0.060
  18. Genome-wide association study identifies high-impact susceptibility loci for HCC in North America. Hepatology. 2024 07 01; 80(1):87-101.
    View in: PubMed
    Score: 0.059
  19. Disruption of Growth Hormone Receptor Signaling Abrogates Hepatocellular Carcinoma Development. J Hepatocell Carcinoma. 2022; 9:823-837.
    View in: PubMed
    Score: 0.053
  20. Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers: A Phase 2 Clinical Trial. JAMA Oncol. 2019 Jun 01; 5(6):824-830.
    View in: PubMed
    Score: 0.043
  21. HER2/neu-directed therapy for biliary tract cancer. J Hematol Oncol. 2015 May 29; 8:58.
    View in: PubMed
    Score: 0.032
  22. Obesity Early in Adulthood Increases Risk but Does Not Affect Outcomes of Hepatocellular Carcinoma. Gastroenterology. 2015 Jul; 149(1):119-29.
    View in: PubMed
    Score: 0.032
  23. Identification of novel therapeutic targets in the PI3K/AKT/mTOR pathway in hepatocellular carcinoma using targeted next generation sequencing. Oncotarget. 2014 May 30; 5(10):3012-22.
    View in: PubMed
    Score: 0.030
  24. Targeted therapy of advanced gallbladder cancer and cholangiocarcinoma with aggressive biology: eliciting early response signals from phase 1 trials. Oncotarget. 2013 Jan; 4(1):156-65.
    View in: PubMed
    Score: 0.027
  25. A phase II study of isoflavones, erlotinib, and gemcitabine in advanced pancreatic cancer. Invest New Drugs. 2011 Aug; 29(4):694-9.
    View in: PubMed
    Score: 0.022
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.